Evidence Grade E — Very limited evidence. 1 published studies. 0 registered clinical trials.
Medically reviewed by a licensed medical professional
HGH Fragment 176-191 is a synthetic piece of human growth hormone investigated for fat loss. The concept was promising in animal studies — mice lost significant fat. But a Phase II clinical trial in approximately 300 people failed to show significant weight loss at any dose, and development was abandoned. It has no regulatory approval.
HGH Fragment 176-191 is also known by these brand and alternate names:
1 published studies: 1 human, 0 animal, 1 in-vitro, 0 reviews
HGH Fragment 176-191 has no marketing authorisation. A Phase IIa trial in obesity (approximately 300 patients) failed to demonstrate statistically significant weight loss at any dose tested. The clinical development programme was discontinued.
The disconnect between animal data (which showed significant fat reduction in obese mice) and the failed human trial is the defining feature of this compound's development history. Products available through unregulated channels lack pharmaceutical quality assurance. The failed Phase II trial represents the highest level of clinical evidence available.
Research in animal models suggested this fragment may stimulate fat breakdown through a mechanism distinct from the growth hormone receptor, without the blood sugar-raising or growth-promoting effects of full growth hormone. However, these animal observations did not translate to human clinical outcomes — the Phase II trial showed no significant effect on weight.
Research suggests the Phase IIa obesity trial (approximately 300 patients) failed to demonstrate statistically significant weight loss at any dose tested. This is the highest level of clinical evidence available and it is negative. The disconnect between animal results and the failed human trial is the defining feature of this compound's history. On the safety side, the fragment does not activate the growth hormone receptor, so it lacks the blood sugar-raising and growth-promoting effects of full growth hormone. Products from unregulated channels lack pharmaceutical quality assurance.
PeptideTrace tracks 0 registered clinical trials for HGH Fragment 176-191 sourced from ClinicalTrials.gov.
No trials registered on ClinicalTrials.gov for this compound.
HGH Fragment 176-191 is a synthetic 16-amino-acid C-terminal fragment of human growth hormone. MW ~1,817 Da. Retains lipolytic properties without diabetogenic, growth-promoting, or anti-natriuretic effects. Does not bind GH receptor or stimulate IGF-1. Not approved. SC 250-500 mcg BID (grey-market, not validated). Half-life ~30 minutes.
Research suggests lipolysis stimulation distinct from GH receptor activation. Proposed interaction with beta-3 adrenergic receptors or downstream HSL activation. Unlike full GH, does not antagonize insulin on glucose uptake. Ng et al. (2000): 50% body fat reduction in obese mice over 3 weeks without IGF-1/lean mass/glucose changes. Exact molecular target unidentified.
No marketing authorization. Phase IIa in obesity (Metabolic Pharmaceuticals; N=~300): no statistically significant weight loss at any dose tested. Program discontinued. Animal data (ob/ob and DIO mice): significant fat loss without food intake/IGF-1/glucose/lean mass changes. Promising animal data did not translate to humans.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Compare prices from 20 vendor listings
View pricing data across vendors and countries for HGH Fragment 176-191
Semaglutide is one of the most extensively studied peptide medications available today, with clinical trial data spanning over 50,000 patients. It is sold as Ozempic for type 2 diabetes (approved 2017), Rybelsus as an oral tablet for diabetes (approved 2019), and Wegovy for weight management (approved 2021). Wegovy has since received additional approvals for reducing heart attack and stroke risk, for use in adolescents aged 12 and older, and for liver disease related to obesity. In clinical trials, patients taking Wegovy lost an average of 14.9% of their body weight over 68 weeks, and the SELECT trial demonstrated a 20% reduction in major cardiovascular events such as heart attack and stroke. Research is now exploring its potential in early Alzheimer's disease. The main side effects are gastrointestinal, particularly nausea, and a key limitation is that most weight tends to return after stopping treatment.
Bimagrumab is in Phase II/III development (not yet approved). A Phase II trial (75 patients with type 2 diabetes and obesity) showed 20.5% fat mass reduction with 3.6% lean mass increase — essentially reshaping body composition without net appetite suppression. The BELIEVE Phase IIb trial (507 patients) showed that bimagrumab plus semaglutide achieved 22% weight loss with the weight lost being 88% fat — significantly better body composition than semaglutide alone. Bimagrumab is not a peptide. Its strategic significance is as a combination partner to address the muscle loss problem inherent in weight loss with current obesity drugs. Eli Lilly's acquisition positions it alongside tirzepatide.
Pemvidutide is in Phase II/III development (not yet approved). In the MOMENTUM Phase II trial (391 patients, 48 weeks), the 2.4 mg dose achieved 15.6% weight loss. Body composition analysis showed 78% of weight lost was fat mass, with only 22% lean mass — a favourable ratio. A Phase IIb MASH trial (212 patients) showed MASH resolution in up to 75% of patients at the highest dose. Pemvidutide's balanced receptor profile and no-titration dosing regimen represent potential practical advantages. The high rate of MASH resolution in Phase II positions it as a candidate for liver disease indications alongside obesity.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
